此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Clinical Trial to Evaluate the Effects of Glow Shakes Premium Collagen Meal Replacement on Nutritional Adequacy, Body Composition, Skin Health, Satiety, and Overall Wellness in Adults Using GLP-1 or Dual-Incretin Medications for Weight Management

2026年11月12日 更新者:The Collagen Co. - GLP-1 Users

This is a single-group, open-label, decentralized clinical trial evaluating the effects of 12 weeks of once-daily consumption of Glow Shakes Premium Collagen Meal Replacement on nutritional adequacy, body composition, skin health, satiety, and overall wellness in 40 adults aged 18-55 years who are currently using a GLP-1 receptor agonist or dual-incretin medication for weight management. All study activities are conducted remotely; participants complete questionnaire assessments and smart scale body composition measurements at home at Baseline, Week 4, Week 8, and Week 12.

Participants replace a typical meal once daily with the study product for 12 consecutive weeks while continuing their existing GLP-1 or dual-incretin medication. The primary objective is to evaluate within-participant change in perceived nutritional adequacy from Baseline to Week 12. Secondary objectives include changes in body fat percentage, muscle mass, perceived skin health, hunger and satiety, hair health, energy and cognitive focus, nail health, gut comfort, metabolism support, physical strength, and product tolerability and satisfaction.

研究概览

研究类型

介入性

注册 (估计的)

40

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Nevada
      • Las Vegas、Nevada、美国、89101
        • Citruslabs

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 65年 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Adults aged 18-55 years at the time of enrollment.
  • Currently using a GLP-1 receptor agonist or dual-incretin medication for weight management (e.g., semaglutide, tirzepatide, liraglutide) for a minimum of 4 weeks at the time of enrollment, with a stable or documented dose (no dose change within the 4 weeks prior to enrollment).
  • Self-reported interest in supporting weight management, lean muscle maintenance, nutritional adequacy, or beauty-related benefits (e.g., skin, hair, nails) during GLP-1 therapy.
  • Willing and able to use Glow Shakes Premium Collagen Meal Replacement as a once-daily meal replacement (replacing a typical meal) for 12 consecutive weeks and to complete all questionnaire assessments and Withings smart scale body composition measurements at Baseline, Week 4, Week 8, and Week 12.
  • Willing and able to maintain current GLP-1 or dual-incretin medication dose throughout the study duration without planned dose adjustments (except in the event of a medically indicated change).
  • Willing to maintain current diet (except for the study product), exercise routine, and lifestyle habits for the duration of the 12-week study, without introducing any new supplements or products specifically targeting weight loss, appetite, or body composition.
  • In good general health.
  • Resides in the United States.

Exclusion Criteria:

  • Pregnant or breastfeeding at the time of enrollment, or planning to become pregnant during the 12-week study period.
  • Known allergy or intolerance to any ingredient in the Glow Shakes formulation, including milk, whey, or collagen-derived ingredients.
  • Diagnosed with a serious medical condition requiring medical nutritional management, including but not limited to Type 1 diabetes, active cancer, or severe renal or hepatic disease.
  • Currently testing, or plan to in the next 12 weeks, a product for another research study.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Glow Shakes Premium Collagen Meal Replacement Arm

Participants will consume one serving once daily - replacing a typical meal such as breakfast or lunch - for 12 consecutive weeks. One serving is prepared by adding the powder to 11.8 fl oz (approximately 350 mL) of water: add water first, then two scoops of powder, and shake for fewer than 10 seconds. Drink immediately after preparation.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in Perceived Nutritional Adequacy
大体时间:Baseline to Week 12

Within-participant change in perceived nutritional adequacy assessed via self-report questionnaire

Baseline to Week 12

次要结果测量

结果测量
措施说明
大体时间
Change in Body Fat Percentage
大体时间:Baseline to Week 12

Within-participant change in body fat percentage (%) measured by participant self-administered Withings smart scale

Baseline to Week 12
Change in Muscle Mass
大体时间:Baseline to Week 12

Within-participant change in muscle mass (kg) measured by participant self-administered Withings smart scale

Baseline to Week 12
Change in Self-Reported Weight Management and Food Cravings
大体时间:Baseline to Week 12

Within-participant change assessed via the validated Food Cravings Questionnaire-Trait Reduced (FCQ-T-reduced)

Baseline to Week 12
Change in Self-Reported Perceived Skin Smoothness
大体时间:Baseline to Week 12

Within-participant change in perceived skin smoothness score assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Perceived Skin Elasticity
大体时间:Baseline to Week 12

Within-participant change in perceived skin elasticity score assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Hunger Intensity
大体时间:Baseline to Week 12

Within-participant change in perceived hunger intensity assessed via visual analogue scale or equivalent validated hunger/satiety instrument

Baseline to Week 12
Change in Self-Reported Satiety Duration
大体时间:Baseline to Week 12

Within-participant change in perceived satiety duration assessed via visual analogue scale or equivalent validated hunger/satiety instrument

Baseline to Week 12
Change in Self-Reported Food Craving Scores
大体时间:Baseline to Week 12

Within-participant change in food craving scores assessed via the Food Cravings Questionnaire-Trait Reduced (FCQ-T-reduced)

Baseline to Week 12
Change in Self-Reported Hair Thickness
大体时间:Baseline to Week 12

Within-participant change in perceived hair thickness assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Hair Health
大体时间:Baseline to Week 12

Within-participant change in perceived hair health assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Energy Levels
大体时间:Baseline to Week 12

Within-participant change in perceived energy levels assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Cognitive Focus
大体时间:Baseline to Week 12

Within-participant change in perceived cognitive focus assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Nail Thickness
大体时间:Baseline to Week 12

Within-participant change in perceived nail thickness assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Nail Health
大体时间:Baseline to Week 12

Within-participant change in perceived nail health assessed via self-report questionnaire

Baseline to Week 12
Change in Gut Comfort and Digestive Health
大体时间:Baseline to Week 12

Within-participant change in gut comfort and digestive symptom scores assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Metabolism Support
大体时间:Baseline to Week 12

Within-participant change in perceived metabolism support assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Physical Strength
大体时间:Baseline to Week 12

Within-participant change in perceived physical strength assessed via self-report questionnaire

Baseline to Week 12
Product Tolerability and Participant Satisfaction
大体时间:Week 12

Participant-reported product satisfaction, acceptability, and tolerability assessed via product satisfaction questionnaire

Week 12

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月1日

初级完成 (估计的)

2027年1月1日

研究完成 (估计的)

2027年1月1日

研究注册日期

首次提交

2026年11月12日

首先提交符合 QC 标准的

2026年11月12日

首次发布 (实际的)

2026年11月18日

研究记录更新

最后更新发布 (实际的)

2026年11月18日

上次提交的符合 QC 标准的更新

2026年11月12日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅